WASHINGTON, DC — In a breakthrough hearing held after lunch and before donor calls, Congress asked pharmacy benefit managers how to lower drug prices and then nodded with relief when the witnesses explained that prices were already performing admirably. Lawmakers praised the clarity, thanked the charts, and agreed that the problem had been misunderstood by patients, pharmacists, physicians, and arithmetic.
The hearing opened with a familiar question about insulin, inhalers, and cancer drugs, followed by an unfamiliar answer about “net costs,” “rebates,” and “value alignment.” Members leaned forward as if attending a magic show. The rabbit appeared. The hat was empty. Everyone applauded the trick. A gavel fell with the confidence of a spreadsheet that cannot be audited.
PBM executives testified that prices rise in public only to fall in private, which is where savings feel safer. They explained that rebates travel through a complex ecosystem and eventually benefit someone, somewhere, at some time. Several members wrote notes. One drew a star. Another circled the word “eventually” and smiled.
A chart showed list prices going up while costs went down, which solved the confusion by replacing it with geometry. A lawmaker asked whether patients notice the savings at the pharmacy counter. The answer explained that noticing is not a required metric. Another lawmaker asked why independent pharmacies keep closing. The response described market efficiency and suggested that efficiency works best without witnesses.
Representatives praised competition among three firms that coordinate across thousands of plans while insisting competition remains fierce because the logos use different shades of blue. The room hummed with bipartisan satisfaction. A staffer whispered that the industry had self-regulated again. A lobbyist nodded, which was taken as peer review.
When asked about prior authorization delays, a witness described guardrails that protect patients from excessive medication. Someone mentioned a patient who waited weeks for approval. The chair thanked them for the anecdote and returned to the slide deck.
As the session closed, Congress concluded that drug prices are low enough for governance and high enough for innovation. Members promised future oversight, possibly during a quarter when nothing else is happening. Cameras clicked. Hands were shaken. Reform was scheduled for later, pending a study to determine whether later exists.
Outside the chamber, patients compared copays and decided to skip refills. Inside, lawmakers congratulated themselves on listening carefully to the people who price listening into the plan. The system remained stable, which was the goal, and stability won again.
